Over the past several years, cancer immunotherapy has made extraordinary progress both conceptually and in clinical practice. The recent FDA approval of drugs in this area has paved the way for many upcoming independent and combination therapies in the immuno-oncology segment.

A variety of strategies are continuing to evolve in the laboratory and in the clinic, including cancer vaccines, T cells, and immune checkpoint blockade.

Despite their promise, much more research is needed to understand how and why certain cancers fail to respond to immunotherapy and to predict which therapeutic strategies, or combinations thereof, are most appropriate for each patient.

The Cancer Immunotherapy Congress will present these ongoing challenges along with some recent technological advances.

Key sessions:

•  Cellular Immunotherapy
•  Predictive Biomarkers for response
• Combinational Therapy and Toxicity
• New Immunotherapy Targets
• Pre-clinical & Translational
• Moving Beyond Current Vaccines